Key facts
- This page summarizes Aron Shapiro's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jun 2026, 16:16.
Aron Shapiro - 10 Jun 2026 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)
- Reporting relationship
- Director
- Issuer ticker
- KPRX
- Reported as of
- 10 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jun 2026, 16:16:08 UTC
- Prior SEC filing
- 02 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Melissa Tosca, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Aron Shapiro filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 12 Jun 2026.
Change
- Previous filing in this sequence was filed on 02 Apr 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001855207
Primary reporting owner
Shapiro Aron
- Relationship
- Director
- Address
- C/O KIORA PHARMACEUTICALS, INC., 169 SAXONY RD., SUITE 212, ENCINITAS
- Signature
- /s/ Melissa Tosca, Attorney-in-Fact
- Signature date
- 11 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KPRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- $0.000000*
- Shares after
- 25,000
- Date
- 10 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $2.63
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.